Clinical trials: Acinetobacter Infections, open to volunteers
Carbapenem-Resistant Acinetobacter Baumannii Infection
Targeted Antimicrobial Comparison for Treatment Individualization in Critically Ill Patients With CRAB Infection
The goal of this prospective, multicenter observational study is to learn which antibiotic treatment strategies are associated with better outcomes in critically ill adults with severe infections caused by carbapenem-resistant…
- Trial name
- TACTIC-CRAB (NCT07905235)
- Testing
- Antibiotic Therapy for CRAB Infection
- Volunteers
- 1,000 people
- Sponsor
- Central South University
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
- Trial name
- CASCADE (NCT05922124)
- Testing
- Cefiderocol, Ampicillin-sulbactam, Colistin
- Where
- 3 sites in Israel
- Volunteers
- 734 people
- Sponsor
- Rambam Health Care Campus
Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection
Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study
This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
- Conditions
- Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection, Pneumonia, Sepsis
- Trial name
- SD-CRAB (NCT07601711)
- Testing
- Sulbactam-Durlobactam
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Provincial People's Hospital
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate…
- Trial name
- NCT06801223
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Innoviva Specialty Therapeutics
Acinetobacter Baumannii Infection
Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii infections in critically ill patients.
- Trial name
- NCT07118384
- Testing
- Cefoperazone-sulbactam injection, Ampicillin - Sulbactam Injection
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Infections, Bacterial, Sepsis Bacterial
Therapeutic Options for CRAB
CRAB infections in ICUs are on the rise, leading to higher morbidity, mortality, and healthcare costs due to resistance to most antibiotics, including carbapenems.
- Trial name
- TheraCRAB (NCT06440304)
- Testing
- Fosfomycin, Eravacycline, ampicillin/sulbactam
- Where
- Croatia
- Volunteers
- 108 people
- Sponsor
- Clinical Hospital Centre Zagreb
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
This Phase IIb study aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC infections.
- Conditions
- Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection, Meningitis, Bacterial
- Trial name
- RIV- CARE (NCT07431307)
- Testing
- BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT)
- Volunteers
- 120 people
- Sponsor
- BioVersys AG
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex…
- Trial name
- NCT06746883
- Testing
- Non-interventional
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Innoviva Specialty Therapeutics